Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T; INDIGO Study Group. Naganuma M, et al. Gastroenterology. 2018 Mar;154(4):935-947. doi: 10.1053/j.gastro.2017.11.024. Epub 2017 Nov 22. Gastroenterology. 2018. PMID: 29174928 Clinical Trial.
Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Kobayashi T, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Takagi T, Omori T, Tahara T, Hisamatsu T; Japanese UC Study Group. Naganuma M, et al. J Gastroenterol. 2024 Apr;59(4):302-314. doi: 10.1007/s00535-024-02079-x. Epub 2024 Jan 26. J Gastroenterol. 2024. PMID: 38277006
Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
Naganuma M, Kobayashi T, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Abe T, Hisamatsu T; Japanese UC Study Group. Naganuma M, et al. J Gastroenterol. 2023 Dec;58(12):1198-1210. doi: 10.1007/s00535-023-02048-w. Epub 2023 Oct 13. J Gastroenterol. 2023. PMID: 37831183
PI5P4K inhibitors: promising opportunities and challenges.
Takeuchi K, Nagase L, Kageyama S, Kanoh H, Oshima M, Ogawa-Iio A, Ikeda Y, Fujii Y, Kondo S, Osaka N, Masuda T, Ishihara T, Nakamura Y, Hirota Y, Sasaki T, Senda T, Sasaki AT. Takeuchi K, et al. FEBS J. 2025 Jan 19. doi: 10.1111/febs.17393. Online ahead of print. FEBS J. 2025. PMID: 39828902 Review.
Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.
Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Fernandez JL, Ishiguro K, Cavaliere M, Deguchi H, Hibi T. Kobayashi T, et al. Among authors: takeuchi k. Intest Res. 2025 Jan 16. doi: 10.5217/ir.2024.00063. Online ahead of print. Intest Res. 2025. PMID: 39818201 Free article.
4,346 results